• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Rhythm Pharmaceuticals Inc.

    5/15/25 6:20:49 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RYTM alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Rhythm Pharmaceuticals, Inc.

    (Name of Issuer)


    Common Stock, $0.001 par value per share

    (Title of Class of Securities)


    76243J105

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    76243J105


    1Names of Reporting Persons

    Perceptive Advisors LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,423,441.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,423,441.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,423,441.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.8 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP No.
    76243J105


    1Names of Reporting Persons

    Joseph Edelman
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,423,441.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,423,441.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,423,441.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.8 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    76243J105


    1Names of Reporting Persons

    Perceptive Life Sciences Master Fund, Ltd.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,965,121.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,965,121.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,965,121.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.5 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    CUSIP No.
    76243J105


    1Names of Reporting Persons

    Perceptive Discovery ID LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,458,330.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,458,330.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,458,330.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    2.2 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Rhythm Pharmaceuticals, Inc.
    (b)Address of issuer's principal executive offices:

    222 Berkely Street, 12th Floor, Boston, MA 02116
    Item 2. 
    (a)Name of person filing:

    The names of the persons filing this report (collectively, the "Reporting Persons") with respect to shares of Common Stock, par value $0.001 per share (the "Common Stock") of Rhythm Pharmaceuticals, Inc. (the "Issuer") are: (i) Perceptive Advisors LLC ("Perceptive Advisors") (ii) Joseph Edelman ("Mr. Edelman") (iii) Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund") (iv) Perceptive Discovery ID LP ("Discovery ID")
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of each of the Reporting Persons is: 51 Astor Place, 10th Floor, New York, NY 10003
    (c)Citizenship:

    Perceptive Advisors is a Delaware limited liability company. Mr. Edelman is a United States citizen. The Master Fund is a Cayman Islands corporation. Discovery ID is a Delaware Limited Liability Company.
    (d)Title of class of securities:

    Common Stock, $0.001 par value per share
    (e)CUSIP No.:

    76243J105
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 of the cover pages to this Schedule 13G. The ownership percentages reported are based on 63,621,472 shares of Common Stock outstanding as of April 30, 2025, as reported in Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 7, 2025, and give effect to the conversion of shares of the Issuer's Series A Convertible Preferred Stock, par value $0.001 per share (the "Series A Convertible Preferred Stock") held by the Reporting Persons at the current Conversion Rate of 20.8333 shares of Common Stock to be issued upon the conversion of each $1,000 of liquidation preference. The Master Fund directly holds 2,548,445 shares of Common Stock. The Master Fund holds Series A Convertible Preferred Stock convertible into 416,666 shares of Common Stock. Discovery ID holds Series A Convertible Preferred Stock convertible into 1,458,330 shares of Common Stock. Perceptive Advisors serves as the investment manager to the Master Fund and may be deemed to beneficially own shares held by the Master Fund. Perceptive Discovery Advisors LP serves as the investment manager to Discovery ID and may be deemed to beneficially own shares held by Discovery ID. Perceptive Discovery GP LLC is the general partner of Discovery ID, and is managed by Perceptive Discovery Advisors LP, a relying advisor of Perceptive Advisors. Mr. Edelman is the managing member of Perceptive Advisors and may be deemed to beneficially own the shares held by the Master Fund and Discovery ID.
    (b)Percent of class:

    Perceptive Advisors: 6.8% Mr. Edelman: 6.8% Master Fund: 4.5% Discovery ID: 2.2
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Perceptive Advisors: 0 Mr. Edelman: 0 Master Fund: 0 Discovery ID: 0

     (ii) Shared power to vote or to direct the vote:

    Perceptive Advisors: 4,423,441 Mr. Edelman: 4,423,441 Master Fund: 2,965,121 Discovery ID: 1,458,330

     (iii) Sole power to dispose or to direct the disposition of:

    Perceptive Advisors: 0 Mr. Edelman: 0 Master Fund: 0 Discovery ID: 0

     (iv) Shared power to dispose or to direct the disposition of:

    Perceptive Advisors: 4,423,441 Mr. Edelman: 4,423,441 Master Fund: 2,965,121 Discovery ID: 1,458,330

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Perceptive Advisors LLC
     
    Signature:/s/ Joseph Edelman
    Name/Title:Joseph Edelman, Managing Member
    Date:05/15/2025
     
    Joseph Edelman
     
    Signature:/s/ Joseph Edelman
    Name/Title:Joseph Edelman
    Date:05/15/2025
     
    Perceptive Life Sciences Master Fund, Ltd.
     
    Signature:/s/ Joseph Edelman
    Name/Title:Joseph Edelman, Managing Member
    Date:05/15/2025
     
    Perceptive Discovery ID LP
     
    Signature:/s/ Joseph Edelman
    Name/Title:Joseph Edelman, Managing Member
    Date:05/15/2025
    Get the next $RYTM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RYTM

    DatePrice TargetRatingAnalyst
    4/7/2025$63.00Neutral → Buy
    BofA Securities
    3/5/2025$78.00Buy
    Stifel
    1/2/2025$80.00Buy
    Jefferies
    12/20/2024$76.00Outperform
    Oppenheimer
    10/21/2024$70.00Buy
    Guggenheim
    9/18/2024$64.00Buy
    H.C. Wainwright
    9/17/2024$64.00Mkt Outperform
    JMP Securities
    5/8/2024$49.00 → $42.00Buy → Neutral
    BofA Securities
    More analyst ratings

    $RYTM
    Financials

    Live finance-specific insights

    See more
    • Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update

      -- First quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $37.7 million -- -- Setmelanotide pivotal Phase 3 TRANSCEND trial met primary endpoint with -19.8% placebo-adjusted BMI reduction in patients (N=120) with acquired hypothalamic obesity -- -- U.S. and EU regulatory submissions for setmelanotide in acquired hypothalamic obesity on track to be completed in the third quarter of 2025 -- -- Topline data from Phase 2 trial of oral MC4R agonist bivamelagon on track to be announced in third quarter of 2025 -- -- Cash on-hand expected to support planned operations into 2027 -- -- Management to host conference call today at 8:00 a.m. ET -- B

      5/7/25 7:00:00 AM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025

      BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, May 7, 2025 to report its first quarter 2025 financial results and provide a corporate update. To access the live conference call, participants may register here. While not required, it is recommended that participants join the call ten minutes prior to the scheduled start. A webcast of the call will also be available under "Events and Presentations" in the Invest

      4/23/25 8:00:00 AM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity

      -- Patients with acquired hypothalamic obesity on setmelanotide therapy (n=81) achieved mean BMI change of -16.5% compared with +3.3% for placebo (n=39) at 52 weeks (p<0.0001) -- -- -19.2% placebo-adjusted BMI reduction achieved in adult patients 18 years old and older (n=49) at 52 weeks -- -- -20.2% placebo-adjusted BMI reduction achieved in patients younger than 18 years old (n=71) at 52 weeks -- -- Regulatory submissions in the U.S. and EU anticipated to be completed in the third quarter of 2025 -- -- Company to host conference call today at 8 a.m. ET -- BOSTON, April 07, 2025 (GLOBE NEWSWIRE) --  Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage bi

      4/7/25 7:00:00 AM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RYTM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access Program

      -- New data showed setmelanotide achieved consistent, meaningful weight reduction -- -- Multiple presentations delivered at the first-ever Joint Congress between the European Society for Paediatric Endocrinology and the European Society of Endocrinology (ESPE-ESE); 32nd annual European Congress on Obesity (ECO); and the 2025 annual meeting of the Pediatric Endocrine Society (PES 2025) -- BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the presentation of new, real-world data at two European congre

      5/14/25 8:00:00 AM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update

      -- First quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $37.7 million -- -- Setmelanotide pivotal Phase 3 TRANSCEND trial met primary endpoint with -19.8% placebo-adjusted BMI reduction in patients (N=120) with acquired hypothalamic obesity -- -- U.S. and EU regulatory submissions for setmelanotide in acquired hypothalamic obesity on track to be completed in the third quarter of 2025 -- -- Topline data from Phase 2 trial of oral MC4R agonist bivamelagon on track to be announced in third quarter of 2025 -- -- Cash on-hand expected to support planned operations into 2027 -- -- Management to host conference call today at 8:00 a.m. ET -- B

      5/7/25 7:00:00 AM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

      BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in fireside chats at three upcoming investor conferences: Bank of America Securities 2025 Healthcare Conference on Wednesday, May 14, 2025 at 12:20 a.m. ETJefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 3:10 p.m. ETGoldman Sachs Annual Healthcare Conference on Monday, June 9, 2025 at 8:00 a.m. ET The fireside chats will be webcasted and availab

      5/6/25 8:00:00 AM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RYTM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rhythm Pharmaceuticals upgraded by BofA Securities with a new price target

      BofA Securities upgraded Rhythm Pharmaceuticals from Neutral to Buy and set a new price target of $63.00

      4/7/25 12:20:34 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel resumed coverage on Rhythm Pharmaceuticals with a new price target

      Stifel resumed coverage of Rhythm Pharmaceuticals with a rating of Buy and set a new price target of $78.00

      3/5/25 7:44:16 AM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Rhythm Pharmaceuticals with a new price target

      Jefferies initiated coverage of Rhythm Pharmaceuticals with a rating of Buy and set a new price target of $80.00

      1/2/25 8:06:46 AM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RYTM
    Leadership Updates

    Live Leadership Updates

    See more

    $RYTM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $RYTM
    SEC Filings

    See more

    $RYTM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer

      BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced the appointment of Alastair "Al" Garfield, Ph.D. as Chief Scientific Officer, effective July 1. "We are excited to welcome Al back to Rhythm as we continue to leverage our understanding of the melanocortin-4 receptor (MC4R) pathway to bring potential therapies to patients and their families," said David Meeker, M.D., Rhythm Chairman, Chief Executive Officer and President. "Al's leadership and established scientific expertise and experience

      7/8/24 8:00:00 AM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rhythm Pharmaceuticals Appoints Dana Washburn, M.D., as Senior Vice President of Clinical Development

      BOSTON, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced the appointment of Dana Washburn, M.D., as Senior Vice President of Clinical Development and as a member of the Company's Executive Leadership Team, effective September 26, 2022. As SVP of Clinical Development, Dr. Washburn will lead the Company's robust clinical development program, clinical operations, and data management. "Dr. Washburn is a collaborative, resourceful leade

      10/6/22 4:02:00 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wren Appoints Bart Henderson as Chief Executive Officer

      Wren Therapeutics, a biopharmaceutical company transforming drug discovery for neurodegenerative diseases, today announced the appointment of Bart Henderson as Chief Executive Officer. Wren's unique drug discovery platform harnesses advances in the biophysics of protein assembly dynamics to target the toxic fleeting protein intermediates, the oligomers, in neurodegenerative disease pathways, and discover small molecules that can block their generation with precision. Bart brings broad leadership experience in the biotechnology industry as a founder and co-founder of several companies including Torque (now Repertoire Immune Medicines), Rhythm (NASDAQ:RYTM) and its subsidiary Motus (acquired

      3/4/22 8:00:00 AM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Rhythm Pharmaceuticals Inc.

      SC 13G - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)

      11/14/24 9:50:26 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Rhythm Pharmaceuticals Inc.

      SC 13G/A - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)

      11/14/24 5:46:11 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Rhythm Pharmaceuticals Inc.

      SC 13G/A - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)

      11/12/24 5:23:38 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Rhythm Pharmaceuticals Inc.

      SCHEDULE 13G/A - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)

      5/15/25 6:20:49 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Rhythm Pharmaceuticals Inc.

      SCHEDULE 13G/A - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)

      5/15/25 4:19:29 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Rhythm Pharmaceuticals Inc.

      SCHEDULE 13G/A - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)

      5/13/25 4:27:00 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Human Resources Officer Cramer Pamela J. sold $457,663 worth of shares (7,031 units at $65.09) and exercised 7,031 shares at a strike of $6.80 (SEC Form 4)

      4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)

      5/1/25 4:53:44 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, Head of International Mazabraud Yann sold $438,946 worth of shares (6,745 units at $65.08), decreasing direct ownership by 15% to 37,655 units (SEC Form 4)

      4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)

      5/1/25 4:52:53 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, Head of International Mazabraud Yann converted options into 21,780 shares, increasing direct ownership by 96% to 44,400 units (SEC Form 4)

      4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)

      4/16/25 4:30:22 PM ET
      $RYTM
      Biotechnology: Pharmaceutical Preparations
      Health Care